THE ISoP MISSION
ISoP is a global, professional, independent, not-for-profit society, open to anyone with an interest in the safe and effective use of medicinal products. ISoP aims to foster science, learning and research in pharmacovigilance in all countries.

We achieve this by providing:

- opportunities for networking in a friendly environment
- collegial and convivial support among fellow pharmacovigilance professionals
- an open and impartial forum for sharing experience, knowledge and solutions
- a platform for discussion and generation of new research and ideas
- meetings, education and affordable training.

Our working language is English.

ISoP MEMBERSHIP BENEFITS

- Reduced fees for the ISoP Annual Meetings, training courses and workshops
- Discounted subscription to the Society’s official journal Drug Safety (online)
- 20% discount and special offers on Wiley books
- ISoP Star – the regular newsletter for ISoP members
- Global networking and exclusive webinars
- ISoP has an internal group in the social media LinkedIn.

HOW TO JOIN ISoP
If you wish to join, please complete the online membership form at www.isoponline.org (under ‘Members’)

administration@isoponline.org

2019 MEMBERSHIP FEES

- Membership for Individual member with online access to Drug Safety, 2019 edition: 215 Euros
- Membership with online access to Drug Safety, 2019 edition
- Student
- Retired / Reduced income
- Low-income / emerging countries: 95 Euros

Payments by bank transfer or credit cards (Amex, Visa, and MasterCard accepted)
A limited number of group discount for corporate employees are available to applicants from low- and middle-income countries. Those who may be eligible should apply to the Applications Committee, c/o ISoP Administration.
A MESSAGE FROM ISoP

We offer an independent, not-for-profit international professional organization, formed and run by voluntary individual members who wish to contribute to better knowledge and understanding, and safer, more effective use of medicines. The Society focuses on the best interests of patients exposed to pharmaceutical interventions in all healthcare systems in the world.

ISoP provides an open platform for professionals from around the world with different expertise and skillsets to network, discuss and exchange information and knowledge in a friendly environment. We organize meetings and training courses in all continents and draw our members from around the world. Through our regional chapters it is also possible to engage in activities supporting patient safety locally. Members can join one of our Special Interest Groups to interact with like-minded experts from other countries or can form a new one. Our recorded lectures on good practice in scientific publishing are available alongside our social media accounts on Twitter and LinkedIn.

ISoP is open to anyone subscribing to the vision and values of the Society. Welcome to our movement for patient safety.

Welcome to ISoP!
Sten Olsson, President

HISTORY OF ISoP

The Society was founded as the European Society of Pharmacovigilance (ESOP) in 1992 and became the International Society of Pharmacovigilance (ISoP) in 2000. ISoP has continued to grow, both in the number of members, and the countries they come from: currently over 600 members from 75 countries in all five continents.

ISoP ADVISORY BOARD 2016 - 2019

Executive Committee:
Sten Olsson, Sweden (President); Ian CK Wong, HK/UK (Vice-President); Mira Harrison-Woolrych, New Zealand (Secretary General); Jean-Christophe Delumeau, Singapore (Treasurer).

Board Members: Hilda Ampadu (Ghana), Brian Edwards (UK), Deirdre McCarthy (USA), Jan Petracek (Czech Republic), Phil Tregunno (UK), Marco Tuccori (Italy); Hervé Le Louët (France, Past President)

Executive Secretary: Sophie Spence

ANNUAL MEETINGS AND TRAINING COURSES

ISoP holds annual meetings which are open to all interested in pharmacovigilance. We are confident that our presence in different parts of the world will stimulate pharmacovigilance and reinforce the truly global nature of ISoP and our spirit of collaboration.

In addition to its annual meeting, ISoP organizes courses on such topics as general drug safety (introductory and advanced levels), case management, risk management, communication, benefit-to-harm assessment, pharmacoepidemiology and related issues. These take place in various countries with international experts.

Full information at www.isoponline.org (under 'Training').

MEETINGS & EVENTS IN 2019

Visit the ISoP website for new training courses and updates.

- **ISoP Mid-year meeting and training**, Nairobi - Kenya 6-8 May
- **ISoP-UMC training course**, Shenzhen - China 20 - 21 September
- **19th Annual Meeting of ISoP**, Bogota - Colombia 26–29 October – the website is www.isop2019bogota.org
- **3rd ISoP Seminar**, Boston - USA 9-10 December

CHAPERS AND SPECIAL INTEREST GROUPS

ISoP members in a country or geographical region are able to form groups to facilitate the organisation of meetings, training courses, or other activities related to the mission of ISoP. Chapters exist in Africa, China, Indonesia, Israel, Italy, Latin America, Mexico, the Middle East, North America, South Asia, South East Europe, Switzerland-Austria, and the Western Pacific region.

ISoP has established Special Interest Groups (SIG) where ISoP members and experts from outside the Society work together on specific topics. Currently the SIGs are ‘Herbal and traditional medicines’, ‘Medication Errors’, ‘PV Professional Qualification Framework’, ‘Women’s Medicine’, ‘Risk Communication’, ‘Risk Minimisation Methods for Asian countries’, and ‘Safety Surveillance of Medical Devices’.

OUR PARTNERS

The official journal of ISoP is Drug Safety, published by Springer.

ISoP is an affiliate of the European Association for Clinical Pharmacology and Therapeutics (EACPT). ISoP is an international member of CIOMS and has close ties with the WHO Programme for International Drug Monitoring and Uppsala Monitoring Centre (UMC). We look forward to closer relationships with other scientific societies which share similar aims to ours, such as the International Society for Pharmacoepidemiology (ISPE).